65,437 trials
Peripheral Arterial Disease (PAD)
Primary: Segment-level Sensitivity and Specificity of VE-MRI at 3 Ferumoxytol Dosing Levels and Differences in Sensitivity and Specificity by Dose Group — 71.8; 76.8; 81.8; 71.2…
Smoking · Smoking Cessation
Primary: Enrollment in Study — 36.5 percentage of people invited who enrolle
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
Primary Hyperoxaluria · Primary Hyperoxaluria Type 1 · Primary Hyperoxaluria Type 2
Primary: Percent Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant Subgroups — -74.06; -68.34; -61.44; -17.98 Percent…
Anorexia Nervosa · Bulimia Nervosa · Anorexia Nervosa, Atypical
Primary: Feasibility of Module Completion — 87.8 percentage of modules completed
Lung Diseases
Primary: System Usability Scale (SUS) — 44.7 units on a scale
Spinal Cord Injuries
Primary: Percentage of Heart Rate Readings Within the Target Zone Achieved During HIT Gait Training Session — 72.67 Percentage of readings
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Overall Survival (OS) in Patients With Haploidentical Family Donors With Hematological Malignancies in Morphological or Radiographic Remission or With Chemosensitive…
Cervical Spine Injury
Primary: Cervical Spine Injury — 274; 159 Participants — p=.05
Coronary Artery Disease
Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L
Aortic Valve Stenosis · Aortic Valve Failure · Aortic Insufficiency
Primary: VARC-2 Defined Event Rate of All Cause Mortality Rate (Percent of Subjects) at 30 Days From the Implant/Index Procedure — 3; 0 Participants
Breast Neoplasm · Prostatic Neoplasm · Colorectal Neoplasms
Primary: Proportion of Patients Reporting Discussion of at Least One Non-ideal or Missing CVH Topic — 96.2; 52.2 Percentage of participants — p=<0.0001
Gene Expression
Primary: Gene Expression — 1; 1; 1; 4 Significantly upregulated genes
Healthy
Primary: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 19.0; 23.5; 16.0 nanogram…
Diabetes Mellitus, Type 2
Primary: Clinical Significant Hypoglycemia — 0; 1 Participants — p=0.6